Targeted therapy in severe asthma today: Focus on immunoglobulin E

Girolamo Pelaia, Giorgio Walter Canonica, Andrea Matucci, Rossella Paolini, Massimo Triggiani, Pierluigi Paggiaro

Research output: Contribution to journalReview article

Abstract

Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes cur­rent knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma.

Original languageEnglish
Pages (from-to)1979-1987
Number of pages9
JournalDrug Design, Development and Therapy
Volume11
DOIs
Publication statusPublished - Jun 29 2017

Fingerprint

Immunoglobulin E
Asthma
Therapeutics
Phenotype
Chronic Disease

Keywords

  • Allergic asthma
  • Anti-immunoglobulin E
  • Global Initiative for Asthma step 5 therapy
  • Omalizumab
  • Phenotypes
  • Severe persistent asthma
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Targeted therapy in severe asthma today : Focus on immunoglobulin E. / Pelaia, Girolamo; Canonica, Giorgio Walter; Matucci, Andrea; Paolini, Rossella; Triggiani, Massimo; Paggiaro, Pierluigi.

In: Drug Design, Development and Therapy, Vol. 11, 29.06.2017, p. 1979-1987.

Research output: Contribution to journalReview article

Pelaia, Girolamo ; Canonica, Giorgio Walter ; Matucci, Andrea ; Paolini, Rossella ; Triggiani, Massimo ; Paggiaro, Pierluigi. / Targeted therapy in severe asthma today : Focus on immunoglobulin E. In: Drug Design, Development and Therapy. 2017 ; Vol. 11. pp. 1979-1987.
@article{549f708885ab4d6abb741137ee1ad89c,
title = "Targeted therapy in severe asthma today: Focus on immunoglobulin E",
abstract = "Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes cur­rent knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma.",
keywords = "Allergic asthma, Anti-immunoglobulin E, Global Initiative for Asthma step 5 therapy, Omalizumab, Phenotypes, Severe persistent asthma, Targeted therapy",
author = "Girolamo Pelaia and Canonica, {Giorgio Walter} and Andrea Matucci and Rossella Paolini and Massimo Triggiani and Pierluigi Paggiaro",
year = "2017",
month = "6",
day = "29",
doi = "10.2147/DDDT.S130743",
language = "English",
volume = "11",
pages = "1979--1987",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Targeted therapy in severe asthma today

T2 - Focus on immunoglobulin E

AU - Pelaia, Girolamo

AU - Canonica, Giorgio Walter

AU - Matucci, Andrea

AU - Paolini, Rossella

AU - Triggiani, Massimo

AU - Paggiaro, Pierluigi

PY - 2017/6/29

Y1 - 2017/6/29

N2 - Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes cur­rent knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma.

AB - Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes cur­rent knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma.

KW - Allergic asthma

KW - Anti-immunoglobulin E

KW - Global Initiative for Asthma step 5 therapy

KW - Omalizumab

KW - Phenotypes

KW - Severe persistent asthma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85024109354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024109354&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S130743

DO - 10.2147/DDDT.S130743

M3 - Review article

AN - SCOPUS:85024109354

VL - 11

SP - 1979

EP - 1987

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -